Research

Cunningham, TJ, Oetinger, M, Blankenhorn EP, Greenstein, JI.Secreted Phospholipase A2 activity in experimental allergic encephalomyelitis and multiple sclerosis. Journal of Neuroinflammation 2006; 3:26

Herndon RM, Greenstein JI. Multiple Sclerosis and Demyelinating Diseases. In: Herndon RM. (Ed) Handbook of Neurologic Rating Scales. 2nd Ed. 2007.

Greenstein JI. Current concepts of the cellular and molecular pathophysiology of Multiple Sclerosis. Developmental Neurobiology 2008; 67:1248-1265.

Cunningham, TJ, Greenstein, JI et al. Uncompetitive Phospholipase A2 inhibition by CHEC sequences including oral treatment of experimental autoimmune myeloencephalitis. The Open Enzyme Inhibition Journal 2009; 2:1-7.

Greenstein JI. Oral disease modifying therapy for MS: Important considerations. Practical Neurology 2011; 10:36 41.

Greenstein JI. Immunemodulation induced by Natalizumab therapy in Multiple Sclerosis. Academy of Neurology Annual Meeting April, 2014

Greenstein JI, Cunningham TJ. Neuroprotective, Anti-inflammatory and Immune Tolerizing properties of peptides derived from Diffusion Survival Evasion Protein (DSEP)/Dermcidin. Academy of Neurology Annual Meeting April, 2014.

Cunningham TJ, Greenstein JI, Loewenstein J, Degermentzidis. Anti-inflammatory peptide regulates supply of heat shock protein 70 monomers: Implications for aging and aging-related disease. Rejuvenation Research. 2015. 18(2):136-144.
 
Buckle G, Bandari BD, Greenstein JI, et al. Effect of delayed-release Dimethyl Fumarate on lymphocyte subsets in patients with Relapsing Multiple Sclerosis: Interim analysis of REALIZE. Consortium of Multiple Sclerosis Centers. 2016 Annual Meeting.
 
Buckle G, Bandari BD, Greenstein JI, et al. Effect of delayed-release Dimethyl Fumarate on lymphocyte subsets in patients with Relapsing Multiple Sclerosis: A retrospective, multicenter, observational study (REALIZE). EP1495 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis.